Early M&A: The Secret of Biotech's Success

As a product-focused biotech with two clinical phase cancer compounds ready to out-license, Wilex stands apart from most of its German--and European--peers. It has got to where it is by virtue of tight focus cost control and an early openness to M&A. Wilex now needs to show it can sign the sort of deals it needs to get to the next level.

Founded in 1998, Wilex AG was one of the first products of the government-funded biotech splurge which kick-started the German biotech industry. But Wilex's product focus and strong cost-control distinguished it from the outset from most of its peers. Reflecting their country's research predilections, most German biotechs were built to offer discovery services based around their technology platforms.

Few investors or entrepreneurs had been through a full round of biotech investment cycles and they thus saw little reason...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Global Vision

Bristol Myers Squibb ASPIREs For Access In LMICs

BMS has launched a new cancer drug access program for low-to-middle income countries, focusing on addressing health inequities and widening accessibility.

This is a test

 

Just running through to check Confluence instructions make sense

H2 Investment Life Sciences Uptick Anticipated But Markets Remain Enduringly Cautious

 
• By 

Taylor Wessing investment partners share their thoughts about market trends, the surge in AI interest and the new UK government’s approach to the life sciences agenda.

WIAT Global: Addressing Inequalities And Following The CAR-T Journey After Treatment

 
• By 

The recent Women in Advanced Therapies Global event, delivered via an interactive 24-hour platform, hosted a number of biopharma speakers who drew on personal and industry-wide experiences, all aligned by a desire to break biases.

More from In Vivo

Vigya test infogram

add a desc test

Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

Clone Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future - Clone

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.